Wall Street brokerages forecast that Mylan NV (NASDAQ:MYL) will announce earnings of $1.13 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Mylan’s earnings. The lowest EPS estimate is $1.09 and the highest is $1.22. Mylan reported earnings per share of $1.17 in the same quarter last year, which would suggest a negative year over year growth rate of 3.4%. The business is expected to issue its next earnings report on Tuesday, November 3rd.
On average, analysts expect that Mylan will report full-year earnings of $4.44 per share for the current fiscal year, with EPS estimates ranging from $4.36 to $4.52. For the next year, analysts expect that the company will post earnings of $4.47 per share, with EPS estimates ranging from $3.74 to $4.76. Zacks’ EPS averages are a mean average based on a survey of analysts that cover Mylan.
Mylan (NASDAQ:MYL) last released its earnings results on Thursday, August 6th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.16. The firm had revenue of $2.73 billion during the quarter, compared to the consensus estimate of $2.74 billion. Mylan had a net margin of 2.35% and a return on equity of 20.43%. The company’s revenue was down 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.03 EPS.
Several research firms have recently commented on MYL. UBS Group boosted their target price on shares of Mylan from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. BidaskClub downgraded shares of Mylan from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 1st. TheStreet raised shares of Mylan from a “d+” rating to a “c” rating in a report on Thursday, August 6th. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $26.00 target price on shares of Mylan in a report on Tuesday, May 12th. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. Mylan has an average rating of “Hold” and an average price target of $20.67.
Shares of NASDAQ:MYL traded up $0.35 during trading on Friday, reaching $15.81. The company had a trading volume of 8,787,237 shares, compared to its average volume of 5,006,359. Mylan has a 12 month low of $12.75 and a 12 month high of $23.11. The company has a fifty day moving average of $16.28 and a two-hundred day moving average of $16.37. The company has a current ratio of 0.93, a quick ratio of 0.53 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $8.17 billion, a P/E ratio of 29.83, a price-to-earnings-growth ratio of 2.11 and a beta of 1.50.
A number of hedge funds have recently bought and sold shares of MYL. Amundi Pioneer Asset Management Inc. increased its position in Mylan by 16.9% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 522,095 shares of the company’s stock valued at $14,796,000 after acquiring an additional 75,655 shares during the last quarter. Raymond James & Associates increased its position in Mylan by 24.6% during the first quarter. Raymond James & Associates now owns 98,372 shares of the company’s stock valued at $1,467,000 after acquiring an additional 19,442 shares during the last quarter. Envestnet Asset Management Inc. bought a new position in Mylan during the first quarter valued at $1,945,000. Dupont Capital Management Corp grew its holdings in shares of Mylan by 43.0% in the first quarter. Dupont Capital Management Corp now owns 15,227 shares of the company’s stock worth $227,000 after purchasing an additional 4,576 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in shares of Mylan by 56.6% in the first quarter. Janney Montgomery Scott LLC now owns 41,194 shares of the company’s stock worth $614,000 after purchasing an additional 14,885 shares during the last quarter. Institutional investors and hedge funds own 88.18% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Article: What’s a Black Swan?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.